Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 1/20 | 0.60 |
| ▸ | HCAR3 | P49019 | 13/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17512440 | 0.88 | HCAR3 (0.62) | CASP6HCAR3TSHRLMNAAPEX1 | |
| SCHEMBL1609806 | 0.82 | CASP6 (0.66) | CASP6HCAR3TSHRPOLBLMNA | |
| SCHEMBL18027781 | 0.82 | CASP6 (0.66) | CASP6HCAR3TSHRPOLBLMNA | |
| SCHEMBL7643058 | 0.81 | CASP6 (0.64) | CASP6HCAR3TSHRPOLBLMNA | |
| SCHEMBL15174048 | 0.81 | CASP6 (0.64) | CASP6HCAR3TSHRPOLBLMNA | |
| Hydrochloric Acid SCHEMBL1609389 | 0.81 | CASP6 (0.64) | CASP6HCAR3TSHRPOLBLMNA | |
| SCHEMBL7712101 | 0.79 | CASP6 (0.62) | CASP6HCAR3TSHRPOLBLMNA | |
| SCHEMBL11789708 | 0.79 | ALDH1A1 (0.44) | CASP6HCAR3TSHRPOLB | |
| SCHEMBL20185172 | 0.78 | CASP6 (0.60) | CASP6HCAR3TSHRPOLBLMNA | |
| SCHEMBL17399916 | 0.78 | CASP6 (0.60) | CASP6HCAR3TSHRPOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101625-B2 | Pyrimidinones as Casein Kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-1948617-B1 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS INC (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20090215803-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. | 2009-08-27 | — | — | US | disclosed |
| EP-1948617-A2 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | Exelixis, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007048065-A2 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215803-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | CSNK2A1, CSNK1A1, CSNK2A2 | CASP6 4705/4885HCAR3 3089/4885TSHR 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.